Disease · MONDO_0016982

angiosarcoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. angiosarcoma. Diseases, record MONDO_0016982. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0016982

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: angiosarcoma; Open Targets
Open Targets ID: MONDO_0016982; Open Targets
Other names: angiosarcoma (disease), blood vessel sarcoma, hemangiosarcoma, hemangiosarcoma, malignant, malignant angioendothelioma, malignant hemangioendothelioma, sarcoma of blood vessel, vascular sarcoma; Open Targets
Disease Ontology: DOID:0001816; Disease Ontology
MeSH: D006394; MeSH
NCI Thesaurus: C3088; NCI Thesaurus
Orphanet: ORPHA:263413; Orphanet
Highest stage of its drugs: Phase 3, for 2 of its 38 drugs, from ClinicalTrials.gov and TTD; Open Targets

Drugs38

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PAZOPANIB	CHEMBL477772	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
CAROTUXIMAB	CHEMBL2109321	Antibody	Phase 3	ClinicalTrials.gov and TTD	4	2	2	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Phase 2	ClinicalTrials.gov	7	7	7	Drugs and targets
PROPRANOLOL	CHEMBL27	Small molecule	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
NIVOLUMAB	CHEMBL2108738	Antibody	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
BALSTILIMAB	CHEMBL4297877	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
DOXORUBICIN	CHEMBL53463	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 38

See all 38 drugs

Targets58

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
KDR	Vascular endothelial growth factor receptor	8	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3791	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	7	Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2321	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	7	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2324	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	6	Stem cell growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3815	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	6	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/5159	Drugs and targets
PDCD1	Programmed cell death protein 1	5	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
PDGFRA	Platelet-derived growth factor receptor	4	Platelet-derived growth factor receptor alpha inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/5156	Drugs and targets
CSF1R	Macrophage colony-stimulating factor 1 receptor	3	Macrophage colony stimulating factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/1436	Drugs and targets
CTLA4	Cytotoxic T-lymphocyte protein 4	3	Cytotoxic T-lymphocyte protein 4 inhibitor	Phase 2	https://conductscience.org/library/genes/1493	Drugs and targets
FGFR1	Fibroblast growth factor receptor 1	3	Fibroblast growth factor receptor 1 inhibitor	Phase 3	https://conductscience.org/library/genes/2260	Drugs and targets

1 to 10 of 58

See all 58 targets

Trials35

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02979899	Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma	Phase 3	128	2020-05-12	Advanced Angiosarcoma	CAROTUXIMAB, PAZOPANIB	Its record names the disease	ClinicalTrials.gov
NCT01975519	A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma	Phase 1/2	111	2020-05-12	Advanced Soft Tissue Sarcoma	CAROTUXIMAB, PAZOPANIB	Its record names the disease	ClinicalTrials.gov
NCT01653028	Alisertib in Treating Patients With Advanced or Metastatic Sarcoma	Phase 2	72	2016-12-28	Myxofibrosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Leiomyosarcoma, Recurrent Liposarcoma, Recurrent Malignant Peripheral Nerve Sheath Tumor, Recurrent Undifferentiated Pleomorphic Sarcoma, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7	ALISERTIB	Its record names the disease	ClinicalTrials.gov
NCT02815995	Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes	Phase 2	57	2025-06-12	Advanced and/or Metastatic Sarcoma	DURVALUMAB, TREMELIMUMAB	Its record names the disease	ClinicalTrials.gov
NCT00288015	Bevacizumab in Treating Patients With Angiosarcoma	Phase 2	32	2018-06-25	Sarcoma	BEVACIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02048722	Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma	Phase 2	31	2020-07-29	Adult Angiosarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma	REGORAFENIB	Its record names the disease	ClinicalTrials.gov
NCT01462630	Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma	Phase 2	29	2022-08-19	Adult Angiosarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma	PAZOPANIB HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT02212015	Evaluation of Votrient in Angiosarcoma	Phase 2	26	2022-03-22	Angiosarcoma	PACLITAXEL, PAZOPANIB	Its record names the disease	ClinicalTrials.gov
NCT01055028	Paclitaxel + Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma	Phase 2	18	2018-03-26	Angiosarcomas, Soft Tissue Sarcoma	BEVACIZUMAB, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT01623869	Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery	Phase 2	16	2015-07-02	Adult Angiosarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma	TREBANANIB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 35

See all 35 trials

Comparisons in its trials10

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
TRC105 + Votrient vs Votrient: deaths from any cause	23 of 64	20 of 64	128	NCT02979899	Trial comparisons
TRC105 + Votrient vs Votrient: Objective Response Rate of Patients With Unresectable Angiosarcoma	3 of 62	8 of 61	123	NCT02979899	Trial comparisons
TRC105 + Votrient vs Votrient: Overall Survival of Patients With Unresectable Angiosarcoma	17 of 62	19 of 61	123	NCT02979899	Trial comparisons
TRC105 + Votrient vs Votrient: serious adverse events	27 of 63	12 of 57	120	NCT02979899	Trial comparisons
8 mg/kg TRC105 + Pazopanib vs 10 mg/kg TRC105 + Pazopanib: deaths from any cause	0 of 3	9 of 106	109	NCT01975519	Trial comparisons
8 mg/kg TRC105 + Pazopanib vs 10 mg/kg TRC105 + Pazopanib: serious adverse events	0 of 3	9 of 106	109	NCT01975519	Trial comparisons
Regimen A / Treatment 1 vs Regimen B / Treatment 2: Overall Survival (OS) at 6 Months	7 of 8	8 of 8	16	NCT01055028	Trial comparisons
Regimen A / Treatment 1 vs Regimen B / Treatment 2: Overall Survival (OS) at 12 Months	6 of 8	6 of 8	16	NCT01055028	Trial comparisons
Regimen A Treatment 1 vs Regimen B Treatment 2: deaths from any cause	0 of 8	0 of 8	16	NCT01055028	Trial comparisons
Regimen A Treatment 1 vs Regimen B Treatment 2: serious adverse events	8 of 8	4 of 8	16	NCT01055028	Trial comparisons

Papers from its trials39

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
22143378	RESULT	1	PubMed
19451433	RESULT	1	PubMed
42499790	DERIVED	1	PubMed
41995270	DERIVED	1	PubMed
41892875	DERIVED	1	PubMed
41836677	DERIVED	1	PubMed
41672597	DERIVED	1	PubMed
41502912	DERIVED	1	PubMed
40588371	DERIVED	1	PubMed
40402690	DERIVED	1	PubMed

1 to 10 of 39

See all 39 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0016982

GET https://conductscience.org/api/diseases/v1/MONDO_0016982/drugs?page=2

API reference For AI assistants